Skip to main content
Premium Trial:

Request an Annual Quote

Oxford BioTherapeutics Licenses Antibody to Sanofi-Aventis for Cancer Drug Development

Premium

Oxford BioTherapeutics announced this week that Sanofi-Aventis has acquired an exclusive worldwide license to one of OBT's preclinical antibody programs.

According to a statement released by OBT, Sanofi-Aventis intends to use the antibody – which is directed against a proprietary target identified by OBT – to develop and commercialize antibody drug conjugate therapies for cancer treatment.

The agreement calls for Sanofi-Aventis to make to OBT an undisclosed upfront cash payment, with OBT eligible for future development, regulatory, and performance milestone payments and royalties on worldwide product sales.

OBT's primary antibody discovery technology is its database of human proteins that it calls the Oxford Genome Anatomy Project, or OGAP. According to the company, OGAP is one of the largest proprietary human cancer cell-surface protein repositories featuring disease protein information "coupled to genetic and clinical data from 50 different human tissues, including 5,000 cancer membrane proteins" and gives "access to information covering 58 disease states."

The deal is OBT's second with a large pharmaceutical company since its founding six years ago. In May 2009 it inked an agreement with GlaxoSmithKline to identify cancer drug targets and develop therapeutic monoclonal antibodies (PM 05/28/2009).

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more